Showing results 3 to 5 of 5
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus Journal:Molecular Cancer Therapeutics | 2015 | ||
2013 | |||
Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A) Proceeding/Conference:Journal of Clinical Oncology | 2010 |